MDM2 as a target for ellagic acid‑mediated suppression of 
prostate cancer cells in vitro

Mohammed Saleem,Yasir I.; Selim,Mustafa I.

doi:10.3892/or.2020.7664

MDM2 as a target for ellagic acid‑mediated suppression of prostate cancer cells in vitro

Authors:
- Yasir I. Mohammed Saleem
- Mustafa I. Selim
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA
Published online on: June 26, 2020 https://doi.org/10.3892/or.2020.7664
Pages: 1255-1265

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is the most common cancer in men. Despite the available treatments for PCa, a significant number of patients relapse as the disease becomes hormonal‑independent. p53 is a common tumor suppressor; however, its activity is diminished via the overexpression of murine double minute‑2 (MDM2). The pomegranate, walnuts, and blueberries are widely consumed fruits and nuts that contain several polyphenolic compounds, mainly ellagic acid (EA). The present study focused on the influence of EA on the p53/MDM2 pathway in PCa cell lines. Three human PCa cell lines PCa LNCaP (p53+/+), 22RV1 (p53−/+), and PC3 (p53−/−) harboring different p53 genotypes were used in this research. We found that EA downregulated the gene and protein expression levels of MDM2 and increased the protein expression of p53 as determined by qPCR and western blot analyses. Moreover, by using western blot analysis, we determined that EA increased the protein expression of the p53 target proteins p21, p53 upregulated modulator of apoptosis (PUMA) [also known as Bcl‑2‑binding component 3 (BBC3)] and Phorbol‑12‑myristate‑13‑acetate‑induced protein 1 (NOXA). Furthermore, we found that EA induced apoptosis in the absence of p53 by downregulating MDM2 and X‑linked inhibitor of apoptosis protein (XIAP) protein expressions as determined by western blot analysis. We conclude that EA suppressed PCa cells in vitro partly by downregulating MDM2.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wirth MP, Hakenberg OW and Froehner M: Antiandrogens in the treatment of prostate cancer. Eur Urol. 51:306–313, discussion 314. 2007. View Article : Google Scholar : PubMed/NCBI
3	Logan IR, McNeill HV, Cook S, Lu X, Lunec J and Robson CN: Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate. 67:900–906. 2007. View Article : Google Scholar : PubMed/NCBI
4	Toufektchan E and Toledo F: The guardian of the genome revisited: p53 downregulates genes required for telomere maintenance, DNA repair, and centromere structure. Cancers (Basel). 10:1352018. View Article : Google Scholar
5	Brady CA and Attardi LD: p53 at a glance. J Cell Sci. 123:2527–2532. 2010. View Article : Google Scholar : PubMed/NCBI
6	Jin L, Li C, Xu Y, Wang L, Liu J, Wang D, Hong C, Jiang Z, Ma Y, Chen Q and Yu F: Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep. 29:1983–1990. 2013. View Article : Google Scholar : PubMed/NCBI
7	Kruse JP and Gu W: SnapShot: p53 posttranslational modifications. Cell. 133:930–30.e1. 2008. View Article : Google Scholar : PubMed/NCBI
8	Muñoz-Fontela C, González D, Marcos-Villar L, Campagna M, Gallego P, González-Santamaría J, Herranz D, Gu W, Serrano M, Aaronson SA and Rivas C: Acetylation is indispensable for p53 antiviral activity. Cell Cycle. 10:3701–3705. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
10	Jimenez GS, Khan SH, Stommel JM and Wahl GM: p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 18:7656–7665. 1999. View Article : Google Scholar : PubMed/NCBI
11	Lee JT and Gu W: The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yuan J, Luo K, Zhang L, Cheville JC and Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 140:384–396. 2010. View Article : Google Scholar : PubMed/NCBI
13	Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
14	Robles AI and Harris CC: Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2:a0010162010. View Article : Google Scholar : PubMed/NCBI
15	Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I and Camara-Lopes LH: Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 14:428–436. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bohlman S and Manfredi JJ: p53-independent effects of Mdm2. Subcell Biochem. 85:235–246. 2014. View Article : Google Scholar : PubMed/NCBI
17	Alarcon-Vargas D and Ronai Z: p53-Mdm2 - the affair that never ends. Carcinogenesis. 23:541–547. 2002. View Article : Google Scholar : PubMed/NCBI
18	Nag S, Qin J, Srivenugopal KS, Wang M and Zhang R: The MDM2-p53 pathway revisited. J Biomed Res. 27:254–271. 2013.PubMed/NCBI
19	Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
20	Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA and Mukhtar H: Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis. 35:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
21	Robson CH, Ganapathy M, Swanson GP, Natarajan M, Papanikolaou N, Hanes MA, Yeh IT, Ghosh R and Kumar AP: Phellodendron amurense bark extract enhances radiosensitivity by inhibition of nf-kappa B in transgenic adenocarcinoma of mouse prostate model and human prostate cancer cells. J Urol. 181((4S)): 4792009. View Article : Google Scholar
22	Paller CJ, Pantuck A and Carducci MA: A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis. 20:265–270. 2017. View Article : Google Scholar : PubMed/NCBI
23	Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG and Heber D: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 16:360–367. 2005. View Article : Google Scholar : PubMed/NCBI
24	Han DH, Lee MJ and Kim JH: Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res. 26:3601–3606. 2006.PubMed/NCBI
25	Naiki-Ito A, Chewonarin T, Tang M, Pitchakarn P, Kuno T, Ogawa K, Asamoto M, Shirai T and Takahashi S: Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis. Prostate. 75:151–160. 2015. View Article : Google Scholar : PubMed/NCBI
26	Losso JN, Bansode RR, Trappey A II, Bawadi HA and Truax R: In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem. 15:672–678. 2004. View Article : Google Scholar : PubMed/NCBI
27	Malik A, Afaq S, Shahid M, Akhtar K and Assiri A: Influence of ellagic acid on prostate cancer cell proliferation: A caspase-dependent pathway. Asian Pac J Trop Med. 4:550–555. 2011. View Article : Google Scholar : PubMed/NCBI
28	Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Cardile V, Kim DH, Abraham NG and Sorrenti V: Apoptotic markers in a prostate cancer cell line: Effect of ellagic acid. Oncol Rep. 30:2804–2810. 2013. View Article : Google Scholar : PubMed/NCBI
29	Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Li Volti G, Cardile V, Abraham NG and Sorrenti V: Effects of ellagic acid on angiogenic factors in prostate cancer cells. Cancers (Basel). 5:726–738. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M and Martins-Green M: Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 35:2321–2330. 2014. View Article : Google Scholar : PubMed/NCBI
31	Zhang HM, Zhao L, Li H, Xu H, Chen WW and Tao L: Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med. 11:92–100. 2014.PubMed/NCBI
32	Mohammed Saleem YI, Albassam H and Selim M: Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner. Eur J Nutr. 59:1607–1618. 2019. View Article : Google Scholar : PubMed/NCBI
33	Van Dross RT: Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog. 48:724–732. 2009. View Article : Google Scholar : PubMed/NCBI
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
35	Nelly Etienne-Selloum ID, Tanveer Sharif CAa and Schini-Kerth VB: Polyphenolic Compounds Targeting p53-Family Tumor Suppressors. Current Progress and Challenges. 2013.
36	Khoo KH, Verma CS and Lane DP: Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
37	Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R and Graziani G: Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. Nutrients. 10:17562018. View Article : Google Scholar
38	Loughery J, Cox M, Smith LM and Meek DW: Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 42:7666–7680. 2014. View Article : Google Scholar : PubMed/NCBI
39	Agrawal A, Yang J, Murphy RF and Agrawal DK: Regulation of the p14ARF-Mdm2-p53 pathway: An overview in breast cancer. Exp Mol Pathol. 81:115–122. 2006. View Article : Google Scholar : PubMed/NCBI
40	Shukla S and Gupta S: Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med. 44:1833–1845. 2008. View Article : Google Scholar : PubMed/NCBI
41	Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W, et al: p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res. 3:627–634. 2005. View Article : Google Scholar : PubMed/NCBI
42	Zhang Z, Wang H, Li M, Agrawal S, Chen X and Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 279:16000–16006. 2004. View Article : Google Scholar : PubMed/NCBI
43	Kracikova M, Akiri G, George A, Sachidanandam R and Aaronson SA: A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 20:576–588. 2013. View Article : Google Scholar : PubMed/NCBI
44	Meek DW and Knippschild U: Posttranslational modification of MDM2. Mol Cancer Res. 1:1017–1026. 2003.PubMed/NCBI
45	Seeram NP, Lee R and Heber D: Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta. 348:63–68. 2004. View Article : Google Scholar : PubMed/NCBI
46	Bell C and Hawthorne S: Ellagic acid, pomegranate and prostate cancer-a mini review. J Pharm Pharmacol. 60:139–144. 2008. View Article : Google Scholar : PubMed/NCBI
47	Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N and Ravi Kumar MN: Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target. 14:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
48	Jeong YI, Prasad Yv R, Ohno T, Yoshikawa Y, Shibata N, Kato S, Takeuchi K and Takada K: Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine. J Pharm Pharmacol. 53:1079–1085. 2001. View Article : Google Scholar : PubMed/NCBI